Anthracycline, Herceptin, and CV Toxicity

R. Scully, A. Miller, Y. Grant, Steven E Lipshultz

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pervasive late effects limit the utility of radiation and chemotherapy, particularly in the pediatric setting, where treatment at a young age often leads to lifelong morbidity and excess mortality. While advances in the understanding of molecular pathways related to tumorigenesis have led to the development of targeted therapies, recurrent late effects and, as in the case of trastuzumab, unexpectedly high rates of cardiotoxicity highlight gaps in our current understanding of drug pathways and the mechanisms of treatment toxicity. Here we review the mechanisms of anthracycline activity in tumor and cardiac cells as well as the clinical manifestations with their associated cardiotoxicity. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.

Original languageEnglish (US)
Title of host publicationCardiovascular Toxicology
PublisherElsevier Inc.
Pages413-427
Number of pages15
Volume6
ISBN (Print)9780080468686
DOIs
StatePublished - Aug 12 2010

Fingerprint

Anthracyclines
Heart Neoplasms
Carcinogenesis
Therapeutics
Radiation
Pediatrics
Morbidity
Drug Therapy
Mortality
Pharmaceutical Preparations
Trastuzumab
Cardiotoxicity

Keywords

  • Antineoplastic antibiotics/adverse effects
  • Cancer survivorship
  • Cardiac biomarkers
  • Cardiomyopathy
  • Cardioprotection
  • Cardiotoxicity
  • Congestive heart failure
  • Dexrazoxane
  • Doxorubicin
  • Echocardiography
  • Epirubicin
  • Idarubicin
  • Late effects
  • Mitoxantrone
  • Monitoring
  • Neuregulin
  • Trastuzumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Scully, R., Miller, A., Grant, Y., & Lipshultz, S. E. (2010). Anthracycline, Herceptin, and CV Toxicity. In Cardiovascular Toxicology (Vol. 6, pp. 413-427). Elsevier Inc.. https://doi.org/10.1016/B978-0-08-046884-6.00726-0

Anthracycline, Herceptin, and CV Toxicity. / Scully, R.; Miller, A.; Grant, Y.; Lipshultz, Steven E.

Cardiovascular Toxicology. Vol. 6 Elsevier Inc., 2010. p. 413-427.

Research output: Chapter in Book/Report/Conference proceedingChapter

Scully, R, Miller, A, Grant, Y & Lipshultz, SE 2010, Anthracycline, Herceptin, and CV Toxicity. in Cardiovascular Toxicology. vol. 6, Elsevier Inc., pp. 413-427. https://doi.org/10.1016/B978-0-08-046884-6.00726-0
Scully R, Miller A, Grant Y, Lipshultz SE. Anthracycline, Herceptin, and CV Toxicity. In Cardiovascular Toxicology. Vol. 6. Elsevier Inc. 2010. p. 413-427 https://doi.org/10.1016/B978-0-08-046884-6.00726-0
Scully, R. ; Miller, A. ; Grant, Y. ; Lipshultz, Steven E. / Anthracycline, Herceptin, and CV Toxicity. Cardiovascular Toxicology. Vol. 6 Elsevier Inc., 2010. pp. 413-427
@inbook{ae2e4ac126c6452b9a8cb790d9a11ef2,
title = "Anthracycline, Herceptin, and CV Toxicity",
abstract = "Pervasive late effects limit the utility of radiation and chemotherapy, particularly in the pediatric setting, where treatment at a young age often leads to lifelong morbidity and excess mortality. While advances in the understanding of molecular pathways related to tumorigenesis have led to the development of targeted therapies, recurrent late effects and, as in the case of trastuzumab, unexpectedly high rates of cardiotoxicity highlight gaps in our current understanding of drug pathways and the mechanisms of treatment toxicity. Here we review the mechanisms of anthracycline activity in tumor and cardiac cells as well as the clinical manifestations with their associated cardiotoxicity. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.",
keywords = "Antineoplastic antibiotics/adverse effects, Cancer survivorship, Cardiac biomarkers, Cardiomyopathy, Cardioprotection, Cardiotoxicity, Congestive heart failure, Dexrazoxane, Doxorubicin, Echocardiography, Epirubicin, Idarubicin, Late effects, Mitoxantrone, Monitoring, Neuregulin, Trastuzumab",
author = "R. Scully and A. Miller and Y. Grant and Lipshultz, {Steven E}",
year = "2010",
month = "8",
day = "12",
doi = "10.1016/B978-0-08-046884-6.00726-0",
language = "English (US)",
isbn = "9780080468686",
volume = "6",
pages = "413--427",
booktitle = "Cardiovascular Toxicology",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Anthracycline, Herceptin, and CV Toxicity

AU - Scully, R.

AU - Miller, A.

AU - Grant, Y.

AU - Lipshultz, Steven E

PY - 2010/8/12

Y1 - 2010/8/12

N2 - Pervasive late effects limit the utility of radiation and chemotherapy, particularly in the pediatric setting, where treatment at a young age often leads to lifelong morbidity and excess mortality. While advances in the understanding of molecular pathways related to tumorigenesis have led to the development of targeted therapies, recurrent late effects and, as in the case of trastuzumab, unexpectedly high rates of cardiotoxicity highlight gaps in our current understanding of drug pathways and the mechanisms of treatment toxicity. Here we review the mechanisms of anthracycline activity in tumor and cardiac cells as well as the clinical manifestations with their associated cardiotoxicity. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.

AB - Pervasive late effects limit the utility of radiation and chemotherapy, particularly in the pediatric setting, where treatment at a young age often leads to lifelong morbidity and excess mortality. While advances in the understanding of molecular pathways related to tumorigenesis have led to the development of targeted therapies, recurrent late effects and, as in the case of trastuzumab, unexpectedly high rates of cardiotoxicity highlight gaps in our current understanding of drug pathways and the mechanisms of treatment toxicity. Here we review the mechanisms of anthracycline activity in tumor and cardiac cells as well as the clinical manifestations with their associated cardiotoxicity. We also describe the cardiac effects of trastuzumab with specific attention to its interaction with anthracyclines.

KW - Antineoplastic antibiotics/adverse effects

KW - Cancer survivorship

KW - Cardiac biomarkers

KW - Cardiomyopathy

KW - Cardioprotection

KW - Cardiotoxicity

KW - Congestive heart failure

KW - Dexrazoxane

KW - Doxorubicin

KW - Echocardiography

KW - Epirubicin

KW - Idarubicin

KW - Late effects

KW - Mitoxantrone

KW - Monitoring

KW - Neuregulin

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85012846185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012846185&partnerID=8YFLogxK

U2 - 10.1016/B978-0-08-046884-6.00726-0

DO - 10.1016/B978-0-08-046884-6.00726-0

M3 - Chapter

SN - 9780080468686

VL - 6

SP - 413

EP - 427

BT - Cardiovascular Toxicology

PB - Elsevier Inc.

ER -